跳至主要内容
临床试验/NCT00314665
NCT00314665终止4 期

Use of Thalidomide in Chronic Uveitis

University of Cincinnati1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2004年1月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
15
试验地点
1
主要终点
Need for corticosteroids to control eyes

研究概览

简要总结

This research study is for patients that have been diagnosed with chronic uveitis, a disease that causes inflammation in the eye. Patients are currently being treated with Remicade, Humira, Methotrexate and or similar chemotherapy type drugs to control this inflammation. Despite these medications, patients still have inflammation in their eyes. Patients are being asked to add an additional drug, thalidomide.

详细描述

Patients will be in the study for approximately 24 weeks. The visits are at screening, baseline (week 0), and weeks 4,8,12, and 24.

The purpose of this research study is to see if Thalidomide is safe and effective in the treatment of patients with chronic inflammation in their eyes. Thalidomide is approved by the Food and Drug Administration (FDA) for a leprosy skin condition, erythema nodosum leprosum (ENL). The drug works in many different ways, including as an anti-inflammation drug. Therefore, it is thought that this drug might be able to improve symptoms and lung function. At this time, the drug is not approved for use for uveitis.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •You are being asked to take part in this research study because you have been diagnosed with chronic uveitis, a disease that causes inflammation in the eye. You are currently being treated with Remicade, Humira, Methotrexate and or similar chemotherapy type drugs to control this inflammation. Despite these medications, you still have inflammation in your eyes. You are being asked to add an additional drug, thalidomide.

排除标准

  • •You will not participate in this research study if any of the following apply to you:
  • •If you are a man or woman not willing to take adequate birth control measures comply with FDA-mandated S.T.E.P.S.â program. .
  • •If you are a breast feeding woman
  • •If you have a significant peripheral neuropathy (numbness or tingling in your hands or feet)
  • •Have had a recent blood clot in your leg or lungs
  • •If you are currently receiving biphosphonates such as zoledronic acid (fosamax)

结局指标

主要结局

Need for corticosteroids to control eyes

Global assessment of ocular status

次要结局

  • Toxicity

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Use of Thalidomide in Chronic Uveitis | 临床试验